Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Respiratory syncytial virus outbreak defined by rapid screening in a neonatal intensive care unit
E.A. Dizdar*, C. Aydemir, O. Erdeve, F.N. Sari, S. Oguz, N. Uras, U. Dilmen

Neonatal Intensive Care Unit, Zekai Tahir Burak Women's Health and Education Hospital, Hamamonu, Ankara, Turkey

Article info
Article history:
Received 12 September 2009
Accepted 13 January 2010
Available online 17 March 2010

Keywords:
Neonatal intensive care unit
Outbreak
Palivizumab
Rapid screening test
Respiratory syncytial virus

Summary
Palivizumab is currently licensed for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants and children with chronic lung disease, with a history of preterm birth, or with haemodynamically significant congenital heart disease, but its routine use during outbreaks in neonatal intensive care units (NICUs) is not currently recommended. Here we report an outbreak in a NICU detected during a screening trial for RSV infection using a rapid antigen test (Respi-Strip). Eleven preterm infants in our NICU tested positive for RSV during January 2009. Subsequent testing of the remaining infants in the NICU revealed two additional asymptomatic cases. In addition to precautions against cross-infection, palivizumab prophylaxis was administered to the remaining 37 premature infants. Two days after treatment, RSV was detected in two additional infants who had become symptomatic. To our knowledge this is the largest RSV outbreak in a NICU to be identified at an early stage by rapid testing and effectively controlled by infection control measures and palivizumab prophylaxis.

Introduction
Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and pneumonia in infants. RSV infection is more severe in premature infants and in those with pre-existing cardiac or pulmonary diseases such as chronic lung disease (CLD). Because of the limited antibody response and reduced concentration of passively acquired maternal antibodies in neonates, preterm neonates are highly susceptible to RSV. Given the high rates of mortality and morbidity in preterm infants, particularly among those with CLD, prophylactic treatment against RSV is recommended in certain situations following exposure.

Palivizumab is a humanised monoclonal antibody directed against the F glycoprotein of RSV. Palivizumab is currently licensed for the prevention of RSV lower respiratory tract disease in infants and children with CLD, with a history of preterm birth or with haemodynamically significant congenital heart disease. It is given monthly by injection during the RSV season and is usually continued for five months in the Northern Hemisphere. However, routine or outbreak use in neonatal intensive care units (NICUs) is not currently recommended.

Here we report an outbreak of RSV which affected 15 hospitalised infants in our NICU, identified at an early stage by rapid testing and controlled by palivizumab prophylaxis and infection control measures.

Methods
Our NICU is a reference centre for central Turkey and serves about 4000 patients annually, including 500 extremely low birth weight neonates. The NICU spans two floors, one of which is exclusively for premature infants. This section has 50 incubators and open beds, although the total capacity of the unit is 120.

Our NICU provides family-centred care, and parents are permitted to visit and take part in the care of their babies, which renders infants susceptible to exposure to external pathogens such as RSV. The RSV season in Turkey is usually between October and April in northern and central regions and between November and April in southern regions of the country. In July 2008 we initiated a screening study to search for cases of RSV infection otherwise overlooked and to determine the real incidence of RSV infection.

Every two weeks infants hospitalised for more than seven days who had respiratory symptoms were screened using Respi-Strip (Coris BioConcept, Gembloux, Belgium). The principle of this
point-of-care immunochromatography test is that a nitrocellulose membrane is sensitised with a monoclonal antibody directed against RSV while a mobile anti-RSV monoclonal antibody is conjugated to colloidal gold particles. If the sample contains RSV, the conjugate–RSV complex will remain bound to the anti-RSV antibody adsorbed onto the nitrocellulose, revealed as a red line that develops on the strip.

Testing was performed in accordance with the manufacturer’s instructions. A nasopharyngeal swab was obtained and placed in a tube containing saline solution and agitated. An aliquot was then mixed with extraction buffer and stirred thoroughly. The strips were then inserted into the tube and incubated for 15 min before reading. The presence of a positive control line with a positive test line was considered a positive result. All tests were performed by the primary investigator (E.A.D.) and testing was available out of working hours throughout the outbreak period. Each box of Respi-Strip was checked with a positive control included in the box before being used in patients.

No cases were found between July and December 2008. However, early in January 2009 screening detected RSV positivity in 11 preterm infants on the same day. Following this, all infants in the NICU were screened, revealing two more cases: these infants were 11 preterm infants on the same day. Following this, all infants in the NICU were screened, visitor numbers were limited, and the unit was closed to healthcare personnel who had respiratory symptoms were also precautions were instituted. Infection control measures were important. Our series indicates that palivizumab prophylaxis along and imposing strict infection control measures are critically important. Our series indicates that palivizumab prophylaxis along with routine infection control measures may prevent the spread of an RSV epidemic in a large unit.

The protection rate of palivizumab from overt clinical RSV infection was 94.6% (35/37 cases). Two cases (4 and 7) developed RSV infection after the implementation of preventive measures and administration of palivizumab. Among the 14 patients who tested positive for RSV by Respi-Strip, all tested positive with PCR, yielding a positive predictive value for Respi-Strip of 100%. Sensitivity and specificity of Respi-Strip could not be determined since not all of the infants who tested negative were subsequently tested by PCR.

**Discussion**

To our knowledge, the RSV outbreak that we experienced in our unit is the first such epidemic to be detected in a NICU by rapid antigen screening. Once an epidemic is identified, screening all infants in the NICU, isolating the symptomatic and infected infants, and imposing strict infection control measures are critically important. Our series indicates that palivizumab prophylaxis along with routine infection control measures may prevent the spread of an RSV epidemic in a large unit.

The incubation period of RSV is 2–8 days but viral shedding may last for up to four weeks. The virus can survive on hard surfaces for up to 7 h and remains detectable after 30 min on cloth, paper, and stethoscopes.4

The use of palivizumab for the control of nosocomial RSV outbreaks has been previously reported by Kurz et al., who successfully prevented an outbreak of RSV in a NICU following the detection of a case.7 Halasa et al. described an RSV outbreak involving nine infected infants.8 Standard infection control measures plus administration of palivizumab to the 49 remaining infants in the NICU were implemented, and no new cases were detected thereafter. Abadesso et al. analysed two RSV outbreaks: although standard infection control measures were effective in the first, five additional infants were infected during a single month in the second.9 Immunoprophylaxis with palivizumab was administered to all of the infants in the

### Table 1

Characteristics of infants with positive respiratory syncytial virus (RSV) screen

| Case no. | Sex | Gestation (weeks) | Birthweight (g) | Age (pre-RSV infection) (days) | O2 support | Outcome |
|----------|-----|-------------------|-----------------|-------------------------------|------------|---------|
| 1        | F   | 33                | 1850            | 6                             | Free O2    | Survived |
| 2        | M   | 31                | 930             | 25                            | Free O2    | Survived |
| 3        | M   | 30                | 1850            | 11                            | Head-box   | Survived |
| 4        | F   | 26                | 950             | 41                            | No         | Survived |
| 5        | M   | 30                | 1580            | 6                             | Nasal CPAP | Died    |
| 6        | F   | 35                | 1280            | 9                             | No         | Survived |
| 7        | M   | 25                | 720             | 37                            | Nasal CPAP | Died    |
| 8        | M   | 29                | 1290            | 23                            | No         | Survived |
| 9        | M   | 29                | 1310            | 51                            | Free O2    | Died    |
| 10       | F   | 32                | 1440            | 16                            | No         | Survived |
| 11       | M   | 31                | 1980            | 14                            | No         | Survived |
| 12       | M   | 31                | 1530            | 33                            | No         | Survived |
| 13       | M   | 28                | 1090            | 25                            | No         | Died    |
| 14       | M   | 30                | 1170            | 22                            | Nasal CPAP | Died    |
| 15       | M   | 30                | 1370            | 12                            | No         | Survived |

CPAP, continuous positive airway pressure.

* Developed RSV infection after palivizumab administration.
NICU and the authors concluded that this helped to prevent an uncontrolled RSV outbreak in their NICU. Cox et al, reported an outbreak of RSV involving seven premature infants. Palivizumab was given to eight high-risk preterm infants and no additional cases occurred.

Fifteen cases of RSV were diagnosed in our NICU, all of which involved patients aged <35 weeks’ gestation. Premature infants are highly susceptible to RSV disease because they have smaller airways, their immune systems are immature, and they have low levels of maternally acquired RSV-specific antibodies. Diagnosis of RSV is largely based on clinical findings, but can also be based on virus isolation, detection of viral antigens or viral RNA, demonstration of a rise in serum antibodies or a combination of these approaches. We used the Respi-Strip RSV rapid antigen test kit, which requires only two reagents (extraction buffer and the immunostrips) and two incubations. It is technically easy to perform, fast (the results were available within 25 min) and accurate (sensitivity of 92% and specificity of 98%). The cost of Respi-Strip is much lower than that of PCR (<$4 vs $136 per patient). Since early detection and implementation of infection control measures are important for outbreak control, rapid antigen testing represents an accurate, fast, and practical method for the diagnosis of RSV infection. Only one infant with negative Respi-Strip test had positive RSV PCR. The remaining infants with negative Respi-Strip test did not develop clinically suspected RSV infection although they were not tested with PCR. Therefore we believe that the sensitivity and specificity of Respi-Strip test are acceptable. However, it should be remembered that the test performance might be affected by the high incidence of the disease during an outbreak and may be lower when used for routine screening.

We were unable to identify the index case in our unit because we had a large number of RSV-infected patients in an outsized NICU. Therefore we decided to give palivizumab to the remaining unaffected high-risk infants in our NICU, even though this is not routinely recommended by current guidelines. We also implemented additional measures including isolation of the positive cases, contact precautions, limitation of visitors and closure to elective admissions. It is difficult to distinguish which, if any, of these interventions altered the course of the outbreak. However, given the high control rate in this study, and previous experience with palivizumab, we believe that palivizumab contributed to the favourable outcome. We detected RSV in two additional patients within 48 h of the administration of palivizumab. This may be explained by false-negativity of the Respi-Strip test during the screening period before palivizumab administration, or ineffectiveness of palivizumab in these patients.

Objective assessment of disease severity was not performed, but we believe that these two cases who developed RSV after palivizumab had milder disease. Eleven of 15 infants with RSV infection developed pneumonia, whereas four infants, including those two who had received prophylaxis, did not. Apnoea, bradycardia, and cough were the major clinical findings, while atelectasis, hyperinflation, and infiltration were the common radiological findings observed in the RSV-infected infants in this study, consistent with previous data. RSV infection should be suspected in the presence of such symptoms, particularly in high-risk patients during the RSV season. The prognosis is somewhat unfavourable and fatal infections may be seen. Seven of our patients required mechanical ventilation, and five with clinical and radiological findings of ARDS died. Severe RSV infections resulting in ARDS with a mortality rate of 40–70% have been reported in the literature. All seven infants who were intubated were born at <31 weeks of gestation, showing that prematurity also negatively affects the course of the disease.

In conclusion, neonatologists should consider RSV infection as a potential cause of fatal outbreaks in the NICU. Respi-Strip represents a feasible, inexpensive, easy-to-perform and fast option for the rapid diagnosis of infection in symptomatic premature babies, particularly during the RSV season. We believe that palivizumab administration is safe and may have a role in controlling RSV outbreaks in the NICU. Further studies are needed to determine the exact role of palivizumab in the optimal control of nosocomial RSV outbreaks.

Conflict of interest statement
None declared.

Funding sources
None.

References
1. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001;344:1917–1928.
2. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982;307:397–400.
3. de Sierra TM, Kumar ML, Wasser TE, Murphy BR, Subbarao EK. Respiratory syncytial virus-specific immunoglobulins in preterm infants. J Pediatr 1993;122:787–791.
4. Policy Statement – Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009;124:1–6.
5. Cardenas S, Auis A, Piedimonte G. Palivizumab in the prophylaxis of respiratory syncytial virus infection. Expert Rev Anti Infect Ther 2005;3:719–726.
6. Bracht M, Heffer M, O’Brien K. Development, implementation, and evaluation of a community- and hospital-based respiratory syncytial virus prophylaxis program. Adv Neonatal Care 2005;5:39–49.
7. Kurz H, Herbrich K, Janata O, Sterniste W, Bauer K. Experience with the use of palivizumab together with infection control measures to prevent respiratory syncytial virus outbreaks in neonatal intensive care units. J Hosp Infect 2008;70:246–252.
8. Halasa NB, Williams JV, Wilson GJ, Walsh WF, Schaffner W, Wright PF. Medical and economic impact of a respiratory syncytial virus outbreak in a neonatal intensive care unit. Pediatr Infect Dis J 2005;24:1040–1044.
9. Abadeso C, Almeida HI, Virella D, Carreiro MH, Machado MC. Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit. J Hosp Infect 2004;58:38–41.
10. Cox RA, Rao P, Brandon-Cox C. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit. J Hosp Infect 2001;48:186–192.
11. Gregson D, Lloyd T, Buchan S, Church D. Comparison of the RSV respi-strip with direct fluorescent-antigen detection for diagnosis of respiratory syncytial virus infection in pediatric patients. J Clin Microbiol 2005;43:5782–5783.
12. Forster J, Schumacher RF. The clinical picture presented by premature neonates infected with the respiratory syncytial virus. Eur J Pediatr 1995;154:901–905.
13. Kilani RA. Respiratory Syncytial Virus (RSV) outbreak in the NICU: description of eight cases. J Trop Pediatr 2002;48:118–122.
14. Heerens AT, Marshall DD, Bose CL. Nosocomial respiratory syncytial virus: a threat in the modern neonatal intensive care unit. J Perinatol 2002;22:306–307.
15. Hammer J, Numa A, Newrth CJ. Acute respiratory distress syndrome caused by respiratory syncytial virus. Pediatr Pulmonol 1997;23:176–183.